GLG News by Dermatologists who Treat Psoriasis (US)
-
Jeffrey WeinbergDirector of Clinical Research - DermatologyST LUKE'S-ROOSEVELT HOSPITAL CENTER
Starpharma gets US patent for use of VivaGel for protection against STIs
September 29, 2009
Starpharma gets US patent for use of VivaGel for protection against STIs | www.pharmabiz.com
Starpharma's lead product, is a vaginal microbicide gel under development for the prevention of sexually transmitted infections (STIs), including genital herpes and HIV infection. The VivaGel® product concept is designed to offer a safe, convenient and affordable means for women to protect themselves from infection with genital herpes and HIV during sex. Surveys show that there is substantial demand in North America and Europe for such a product with an estimated billion dollar market for STI prevention products in the developed world.
-
Jeffrey WeinbergDirector of Clinical Research - DermatologyST LUKE'S-ROOSEVELT HOSPITAL CENTER
Stelara new Option for Psoriasis
September 26, 2009
Stelara Approved to Treat Moderate to Severe Plaque Psoriasis in Adults | www.webmd.com
The FDA approved Stelara based on three studies of 2,266 patients who either got shots of Stelara or a placebo. Patients who got Stelara were more likely to achieve the studies' benchmark for reduction in psoriasis.In a news release, the FDA notes that because Stelara reduces the immune system's ability to fight infections, the product poses a risk of infection. "Serious infections have been reported in patients receiving the product and some of them have led to hospitalization. These infections were caused by viruses, fungi, or bacteria that have spread throughout the body. There may also be an increased risk of developing cancer," the FDA states.
-
Jeffrey WeinbergDirector of Clinical Research - DermatologyST LUKE'S-ROOSEVELT HOSPITAL CENTER
June 23, 2008
Positive news on J&J's ustekinumab diminished by safety concerns - analysts | www.tradingmarkets.com
On Tuesday, the FDA's Dermatologic and Ophthalmic Drug Advisory Panel voted unanimously to approve the use of the injectable drug for the treatment of plaque psoriasis, a severe skin disease. As the FDA usually follows the recommendations of its advisory panels when reviewing new drugs for approval, it is anticipated that the regulatory body will approve the drug in the fourth quarter, analysts said. But concerns over the drug's carcinogenic potential and the panel's recommendation that the drug be administered only by a physician and not directly by the patient could diminish enthusiasm over ustekinumab and lessen the drug's potential market share.
-
Jeffrey WeinbergDirector of Clinical Research - DermatologyST LUKE'S-ROOSEVELT HOSPITAL CENTER
December 19, 2007
This drug is four times yearly This will be attractive to MDs and patients It is highly efficaciuous
-
Kenneth EdelsonAssociate Clinical Professor of DermatologyMOUNT SINAI SCHOOL OF MEDICINE
December 17, 2007
Ipsen and Medicis announce submission of Reloxin(R) in aesthetics to the FDA | www.pipelinereview.com
Lowering cost of Botox is key, but not enough to induce patients to undergo Botox treatments.
-
Kenneth EdelsonAssociate Clinical Professor of DermatologyMOUNT SINAI SCHOOL OF MEDICINE
Reloxin Gives Allergan's Botox A Run for the Money!
December 13, 2007
Ipsen and Medicis announce submission of Reloxin(R) in aesthetics to the FDA | www.pipelinereview.com
For too long Allergan has monopolized the therapeutic and cosmetic market of botulinum toxin type A, and has taken full advantage of that monopoly by raising the price of Botox almost biannually. Reloxin studies are very favorable when compared to Botox, and may even surpass it in one or two aspects. There is a lesser protein load and therefore less antigenic than Botox and this may lead to a longer lasting effect. Studies already show and support this. In addition, there is a greater diffusion of the toxin from pontiff injection, and this is desirable in certain areas as the large frontalis areas of the face, and certainly in the large areas we tret for hyperhidrosis of the palms, soles and axillae, The conversion rate of units is not to be looked at as a chore of conversion, but as learning a new language. Don't look to convert units to units...just learn the required units of the new toxin. The shelf life appears to be slily longer as well. Cudos to Reloxin-watch out Botox!
-
Kenneth EdelsonAssociate Clinical Professor of DermatologyMOUNT SINAI SCHOOL OF MEDICINE
New Organiceuticals May Help Bring Back Beauty!
May 29, 2007
http://www.nytimes.com/2007/04/26/fashion/26skin.html?_r=1&ref=health&oref=slogin | www.nytimes.com
All that glitters is not gold...but some might be! Anti-oxidants are the promise of saving our "hides"!
-
Kenneth EdelsonAssociate Clinical Professor of DermatologyMOUNT SINAI SCHOOL OF MEDICINE
May 28, 2007
FDA May Place Ban on OTC Bleaching Creams | www.carefair.com
Keep Hydroquinones Around!
-
Kenneth EdelsonAssociate Clinical Professor of DermatologyMOUNT SINAI SCHOOL OF MEDICINE
Non-Invasive Screening of the Skin
May 17, 2007
New tool allows noninvasive screening of skin lesions | www.modernmedicine.com
The company hopes to apply for European regulatory approval next year, with U.S. market approval and launch to follow. The current price of the device is 15,000 EUR. This device promises to be a remarkable time and money saver for medicine. Approximately 80-95% of lesions excised by dermatologists prove non-cancerous when examined histologically. This is wasted time, money and unnecessary anxiety for patients.
-
Kenneth EdelsonAssociate Clinical Professor of DermatologyMOUNT SINAI SCHOOL OF MEDICINE
Pulsed Dye Vs Excimer Laser for Psoriasis
May 17, 2007
Psoriasis Challenge: pulsed dye vs. excimer lasers | www.modernmedicine.com
Patient satisfaction is high, but long term effects including possible carcinogenesis remain uncertain. Side effects included blistering, and hyperpigmentation in both groups, but no scarring.
Leading institutions connect with members of the Healthcare councils through GLG
Most Popular Healthcare News
-
February 7, 2012
-
What do the cloud, collaboration and virtualization have in common?
January 27, 2012
-
Clinical diagnostic acquisitions dominate 2011 top ten list
January 12, 2012
-
Gene therapy success threatens drugs for hemophilia and rare diseases
December 13, 2011
-
Medtech M&A activity accelerates in 2011
November 30, 2011
Gerson Lehrman Group, Inc. connects communities with knowledge through two distinct, yet complementary offerings: GLG Research and G+.